0.1693
price down icon3.42%   -0.006
after-market  After Hours:  .1777  0.0084   +4.96%
loading
ReShape Lifesciences Inc. stock is currently priced at $0.1693, with a 24-hour trading volume of 72,742. It has seen a -3.42% decreased in the last 24 hours and a -3.26% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.173 pivot point. If it approaches the $0.168 support level, significant changes may occur.
Previous Close:
$0.1753
Open:
$0.175
24h Volume:
72,742
Market Cap:
$3.97M
Revenue:
$9.81M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.00264
EPS:
-64.04
Net Cash Flow:
$-17.45M
1W Performance:
-0.29%
1M Performance:
-3.26%
6M Performance:
-32.82%
1Y Performance:
-93.20%
1D Range:
Value
$0.1676
$0.179
52W Range:
Value
$0.1414
$2.798

ReShape Lifesciences Inc. Stock (RSLS) Company Profile

Name
Name
ReShape Lifesciences Inc.
Name
Phone
949 429 6680
Name
Address
1001 Calle Amanecer, San Clemente
Name
Employee
47
Name
Twitter
Name
Next Earnings Date
2024-05-13
Name
Latest SEC Filings
Name
RSLS's Discussions on Twitter

ReShape Lifesciences Inc. Stock (RSLS) Financials Data

ReShape Lifesciences Inc. (RSLS) Revenue 2024

RSLS reported a revenue (TTM) of $9.81 million for the quarter ending September 30, 2023, a -13.01% decline year-over-year.
loading

ReShape Lifesciences Inc. (RSLS) Net Income 2024

RSLS net income (TTM) was -$26.16 million for the quarter ending September 30, 2023, a +60.61% increase year-over-year.
loading

ReShape Lifesciences Inc. (RSLS) Cash Flow 2024

RSLS recorded a free cash flow (TTM) of -$17.45 million for the quarter ending September 30, 2023, a +22.83% increase year-over-year.
loading

ReShape Lifesciences Inc. (RSLS) Earnings per Share 2024

RSLS earnings per share (TTM) was -$38.77 for the quarter ending September 30, 2023, a +77.99% growth year-over-year.
loading
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
medical_devices STE
$207.82
price up icon 0.77%
$287.87
price up icon 0.46%
medical_devices PHG
$26.82
price up icon 0.98%
medical_devices ZBH
$121.66
price up icon 2.70%
$128.37
price up icon 1.36%
medical_devices EW
$85.25
price up icon 0.22%
Cap:     |  Volume (24h):